- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Crinecerfont therapy tied to reduced adrenal androgen production and lower glucocorticoid administration in CAH patients: NEJM
USA: A Phase 3 clinical trial has demonstrated that crinecerfont, a novel therapeutic agent, significantly reduces glucocorticoid doses in adults with congenital adrenal hyperplasia (CAH). This promising outcome marks a significant step forward in managing CAH, a genetic disorder characterized by enzyme deficiencies that lead to excess adrenal androgens and require lifelong glucocorticoid treatment.
In patients with congenital adrenal hyperplasia, crinecerfont treatment led to a more substantial reduction from baseline in the mean daily glucocorticoid dose, including a decrease to the physiological range, compared to placebo, following the assessment of adrenal androgen levels, the researchers wrote in the New England Journal of Medicine.
In patients with classic 21-hydroxylase deficiency CAH, adrenal insufficiency is managed with glucocorticoid replacement therapy. To control excess adrenal-derived androgens, patients often require supraphysiologic glucocorticoid doses, which can lead to complications related to glucocorticoid use. In Phase 2 trials, crinecerfont, an oral antagonist of the corticotropin-releasing factor type 1 receptor, demonstrated efficacy by lowering androstenedione levels in individuals with CAH.
Against the above background, Richard J. Auchus, University of Michigan Medical School, Ann Arbor, Michigan, and colleagues randomly assigned adults with CAH in a 2:1 ratio to receive crinecerfont or placebo for 24 weeks. Glucocorticoid treatment was held at a constant level for four weeks to assess androstenedione levels. Following this period, the glucocorticoid dose was gradually reduced and optimized over 20 weeks to find the lowest effective dose that kept androstenedione levels under control (≤120% of baseline or within the reference range).
The primary efficacy endpoint was the percentage change in the daily glucocorticoid dose from baseline to week 24 while maintaining control of androstenedione levels.
The following were the key findings of the study:
- In the 24-week analysis, all 182 patients who underwent randomization (122 to the crinecerfont group and 60 to the placebo group) were included, with the imputation of missing values; 97% remained in the trial at week 24.
- The mean glucocorticoid dose at baseline was 17.6 mg per square meter of body-surface area per day of hydrocortisone equivalents; the mean androstenedione level was elevated at 620 ng per deciliter.
- At week 24, the change in the glucocorticoid dose (with androstenedione control) was −27.3% in the crinecerfont group and −10.3% in the placebo group.
- A physiologic glucocorticoid dose (with androstenedione control) was reported in 63% of the patients in the crinecerfont group and 18% in the placebo group.
- At week 4, androstenedione levels decreased with crinecerfont (−299 ng per deciliter) but increased with placebo (45.5 ng per deciliter).
- Fatigue and headache were the most common adverse events in the two trial groups.
The findings of the study offer hope for a new therapeutic approach for CAH patients, who have traditionally relied on high doses of glucocorticoids with significant potential for adverse effects.
The researchers concluded that crinecerfont’s potential to reduce these doses while effectively managing the disease marks a significant advancement in the field.
Reference:
Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB Jr, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH; CAHtalyst Adult Trial Investigators. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. N Engl J Med. 2024 Jun 1. doi: 10.1056/NEJMoa2404656. Epub ahead of print. PMID: 38828955.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751